On the Development of Novel Antibiotics -Ted Schroeder - Nabriva Therapeutics
Finding Genius Podcast
Richard Jacobs
4.4 • 1K Ratings
🗓️ 3 January 2020
⏱️ 19 minutes
🔗️ Recording | iTunes | RSS
🧾️ Download transcript
Summary
For over 30 years, Ted Schroeder has been involved in the sales, marketing, and development of antibiotics, and he currently serves as the CEO of Nabriva Therapeutics. He joins the podcast today to discuss the current work being done at Nabriva, which involves the development of a new class of IV antibiotics for the treatment of community-acquired pneumonia in adults—the first of its kind in the US in over two decades.
 The second product Nabriva is working on has been around for nearly four decades but has never been available in the US, and it's been shown to be effective in tackling complicated urinary tract infections and multidrug-resistant strains of bacteria. These antibiotics could limit or altogether eliminate the need for hospital stays for many people. To learn more about the work being done, tune in.
You'll discover the details of all this and more, including:
- What makes gram negative bacterial infections so much more difficult to treat than gram-positive bacterial infections
- How strong the clinical-based evidence is for the effectiveness of these antibiotics
- What's on the horizon in the near future for Nabriva Therapeutics, pharmacology, and anti-infective agents
For more information, visit https://www.nabriva.com/.
Transcript
Click on a timestamp to play from that location
| 0:00.0 | You're listening to the Future Tech Podcast with Richard Jacobs. |
| 0:09.0 | Future Technologies such as Artificial Intelligence, |
| 0:11.8 | Stem Cells, 3D printing, gene editing, |
| 0:14.7 | Bitcoin, blockchain, the microbiome, quantum computing, virtual reality, and exploring space |
| 0:21.0 | are much closer than you might think. |
| 0:23.0 | In fact, many early versions of these technologies are in play right now, |
| 0:27.0 | and the companies that are using these technologies |
| 0:30.0 | for the focus of this podcast. |
| 0:32.0 | My goal for you, the listener, is to learn from these |
| 0:34.4 | podcasts. You may very well learn something that may change the course of your life |
| 0:38.2 | for the better, steer you towards a new career, or give you insight into |
| 0:42.4 | addressing a thorny medical problem. |
| 0:44.4 | Remember, this podcast and its content is informational and nature only. No medical, |
| 0:49.2 | tax, legal, financial, or psychological advice is being given. |
| 0:53.0 | If you've enjoyed the podcast, please listen, subscribe, like, and tell your friends about it. |
| 0:58.0 | Thank you. Hello, this is Richard Jacobs with the Future Tech and Future Tech Health Podcast. I have Ted Schroeder. He's the CEO of a company called Negriva, N-A-B-R-I-V-A, Debriva therapeutics. |
| 1:15.8 | Ted, thanks for coming. |
| 1:16.8 | Hey Richard, thanks for inviting me on. |
| 1:19.8 | I really appreciate it. |
| 1:20.8 | Yeah, tell me, this is probably a strange question. |
| 1:23.0 | What does the word Nebriva come from? |
| 1:25.0 | So it's an acronym and it actually stands for the origins of our company, |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Richard Jacobs, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Richard Jacobs and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2026.